Norma Maugeri

Dr. Norma Maugeri

IRCCS Ospedale San Raffaele, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2014 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
NMNorma Maugeri
Norma Maugeri
LCL. Campana
L. Campana
MGM. Gavina
M. Gavina
CCC. Covino
C. Covino
MMM. De Metrio
M. De Metrio
AMA. A. Manfredi
A. A. Manfredi

8 January 2019 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
SBSebastian Boeltz
Sebastian Boeltz
PAPoorya Amini
Poorya Amini
HAHans-Joachim Anders
Hans-Joachim Anders
FAFelipe Andrade
Felipe Andrade
Rostyslav BilyyRostyslav Bilyy
Rostyslav Bilyy
MHMartin Herrmann
Martin Herrmann
Since the discovery and definition of neutrophil extracellular traps (NETs) 14 years ago, numerous characteristics and physiological functions of NETs have been uncovered. Nowadays, the field continues to expand and novel mechanisms that orchestrate formation of NETs, their previously unknown properties, and novel implications in disease continue to emerge. The abundance of available data has also led to some confusion in the NET research community due to contradictory results and divergent scientific concepts, such as pro- and anti-inflammatory roles in pathologic conditions, demarcation from other forms of cell death, or the origin of the DNA that forms the NET scaffold. Here, we present prevailing concepts and state of the science in NET-related research and elaborate on open questions and areas of dispute.

24 May 2021 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
MAMaximilian Ackermann
Maximilian Ackermann
HAHans-Joachim Anders
Hans-Joachim Anders
Rostyslav BilyyRostyslav Bilyy
Rostyslav Bilyy
GBGary L. Bowlin
Gary L. Bowlin
CDChristoph Daniel
Christoph Daniel
Martin HerrmannMartin Herrmann
Martin Herrmann
SARS-CoV-2 infection poses a major threat to the lungs and multiple other organs, occasionally causing death. Until effective vaccines are developed to curb the pandemic, it is paramount to define the mechanisms and develop protective therapies to prevent organ dysfunction in patients with COVID-19. Individuals that develop severe manifestations have signs of dysregulated innate and adaptive immune responses. Emerging evidence implicates neutrophils and the disbalance between neutrophil extracellular trap (NET) formation and degradation plays a central role in the pathophysiology of inflammation, coagulopathy, organ damage, and immunothrombosis that characterize severe cases of COVID-19. Here, we discuss the evidence supporting a role for NETs in COVID-19 manifestations and present putative mechanisms, by which NETs promote tissue injury and immunothrombosis. We present therapeutic strategies, which have been successful in the treatment of immunο-inflammatory disorders and which target dysregulated NET formation or degradation, as potential approaches that may benefit patients with severe COVID-19.

20 February 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AMAngelo A. Manfredi
Angelo A. Manfredi
GRGiuseppe A. Ramirez
Giuseppe A. Ramirez
PRPatrizia Rovere-Querini
Patrizia Rovere-Querini
NMNorma Maugeri
Norma Maugeri
Neutrophils recognize particulate substrates of microbial or endogenous origin and react by sequestering the cargo via phagocytosis or by releasing neutrophil extracellular traps (NETs) outside the cell, thus modifying and alerting the environment and bystander leukocytes. The signals that determine the choice between phagocytosis and the generation of NETs are still poorly characterized. Neutrophils that had phagocytosed bulky particulate substrates, such as apoptotic cells and activated platelets, appear to be “poised” in an unresponsive state. Environmental conditions, the metabolic, adhesive and activation state of the phagocyte, and the size of and signals associated with the tethered phagocytic cargo influence the choice of the neutrophils, prompting either phagocytic clearance or the generation of NETs. The choice is dichotomic and apparently irreversible. Defects in phagocytosis may foster the intravascular generation of NETs, thus promoting vascular inflammation and morbidities associated with diseases characterized by defective phagocytic clearance, such as systemic lupus erythematosus. There is a strong potential for novel treatments based on new knowledge of the events determining the inflammatory and pro-thrombotic function of inflammatory leukocytes.

17 May 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
AVAndrea Valle
Andrea Valle
GGGian Maria Giamporcaro
Gian Maria Giamporcaro
MSMarina Scavini
Marina Scavini
ASAngela Stabilini
Angela Stabilini
PGPauline Grogan
Pauline Grogan
MBManuela Battaglia
Manuela Battaglia
Human type 1 diabetes (T1D) is an autoimmune disease associated with major histocompatibility complex polymorphisms, β-cell autoantibodies, and autoreactive T cells. However, there is increasing evidence that innate cells may also play critical roles in T1D. We aimed to monitor peripheral immune cells in early stages of T1D (i.e., in healthy autoantibody-positive subjects) and in more advanced phases of the disease (i.e., at disease onset and years after diagnosis). We found a mild but significant and reproducible peripheral neutropenia that both precedes and accompanies the onset of T1D. This reduction was not due to peripheral neutrophil cell death, impaired differentiation, or the presence of anti-neutrophil antibodies. Neutrophils were observed by electron microscopy and immunohistochemical analysis in the exocrine pancreas of multiorgan donors with T1D (both at onset and at later stages of the disease) and not in that of multiorgan donors with type 2 diabetes or nondiabetic donors. These pancreas-infiltrating neutrophils mainly localized at the level of very small blood vessels. Our findings suggest the existence of a hitherto unrecognized clinical phenotype that might reflect unexplored pathogenic pathways underlying T1D.

25 July 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
NMNorma Maugeri
Norma Maugeri
ACAnnalisa Capobianco
Annalisa Capobianco
PRPatrizia Rovere-Querini
Patrizia Rovere-Querini
GRGiuseppe A. Ramirez
Giuseppe A. Ramirez
ETEnrico Tombetti
Enrico Tombetti
AMAngelo A. Manfredi
Angelo A. Manfredi
Platelet microparticles from patients with systemic sclerosis prompt endothelial cell activation, neutrophil recruitment, and lung fibrosis.